Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Ist Innuscreen GmbH has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, indicating separate examination contexts within the current docket.
OLSON, ANDREA STEFFEL is the busiest examiner, with 1 pending matter. Counsel should maintain matter-specific response strategies while reviewing the two records for any genuinely shared scientific or claim issues. The available data does not show a common examiner or art unit that would support a single unified approach.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
| GERIDO, DWAN A | 1 | 58.1% | +30.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707767 | METHOD FOR CASCADABLE CONCENTRATION OF AT LEAST ONE TARGET SUBSTANCE IN A SAMPLE LIQUID | GERIDO, DWAN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707767 | METHOD FOR CASCADABLE CONCENTRATION OF AT LEAST ONE TARGET SUBSTANCE IN A SAMPLE LIQUID | GERIDO, DWAN A | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| 1797 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18710265 | METHOD AND TEST KIT FOR THE COST-EFFECTIVE AND RESOURCE-SAVING EXTRACTION OF NUCLEIC ACIDS | OLSON, ANDREA STEFFEL | 1623 | §102Other | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18707767 | METHOD FOR CASCADABLE CONCENTRATION OF AT LEAST ONE TARGET SUBSTANCE IN A SAMPLE LIQUID | GERIDO, DWAN A | 1797 | §102§103§112 | Non-Final OA | — | Pending | May 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIst Innuscreen GmbH has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Andrea Steffel Olson has the most, with 1 of Ist Innuscreen GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
